Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.

Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people with pancreatic cancers whose response to standard immunotherapy is poor.

Families and caregivers of people with cancer may view the holidays as a particularly challenging time, often feeling as though they have to live up to the ideal of merry and bright, when they--and those they're tending--typically don't feel that way. Cedars-Sinai experts offer 6 tips for making the most of the holidays while caring for someone with cancer.

Assistant Professor Iram Surtaj will use a new imaging technique to identify drugs that can disrupt overexpression of multidrug resistance protein 1, one of the main mechanisms through which cancer cells gain resistance to chemotherapy drugs.

The largest study to date to compare exposure to toxicants among users of electronic cigarettes, smokers and nonsmokers has been completed, suggesting possible benefits for smokers who switch completely to electronic cigarettes

A new study by UCLA scientists shows that enhancers, snippets of DNA that contribute to gene regulation, fall into the same "insulated neighborhoods" or chromatin loops as the target gene and other gene-specific regulatory elements.

In general, women who have had children have a lower risk of breast cancer compared to women who have never given birth. However, new research has found that moms don't experience this breast cancer protection until many years later and may face elevated risk for more than 20 years.

Pediatric oncologist and researcher Yael Mosse, MD, Director of the Neuroblastoma Development Therapeutics Program at Children's Hospital of Philadelphia, has been named the inaugural holder of the Patricia Brophy Endowed Chair in Neuroblastoma Research.

New research out of Roswell Park Comprehensive Cancer Center shows that cancer patients who exercise regularly both before and after their diagnosis are significantly more likely to survive than those who are sedentary, adding to the growing body of evidence that physical activity is an important part of a cancer prevention and treatment strategy. The results were published in a recent issue of the journal Cancer Causes & Control.

Hackensack Meridian Health and the Meridian Health Foundation are pleased to announce a gift of $750,000 from the Nicola-Musso Charitable Foundation of New York, N.Y. and Carol Musso Foley of New York and Spring Lake, NJ, to be used to enhance cancer care services at Hackensack Meridian Health Jersey Shore University Medical Center and Hackensack Meridian Health Ocean Medical Center.

Weizmann Institute scientists Profs. Ido Amit and Amos Tanay, working with hemato-oncologists, have created a new way to profile myeloma tumor cells. The machine-learning-based technique will allow earlier and better diagnosis of the cancer, including in terms of relapse, and improve treatment.

A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The finding, published Nov. 7 in Nature Communications, could eventually lead to new targets for cancer-fighting therapeutics.

A collaborative group of researchers co-led by a UNC Lineberger Comprehensive Cancer Center scientist found that, in women 55 years and younger, breast cancer risk peaked about five years after they gave birth, with risk for mothers 80 percent higher compared with women who did not give birth.

Many people who are diagnosed with cancer will undergo some type of surgery to treat their disease -- almost 95 percent of people with early-diagnosed breast cancer will require surgery and it's often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure.

The University of Kansas Cancer Center and the the Midwest Cancer Alliance co-hosted an introductory training workshop for individuals who want to learn more about KU Cancer Center's patient research advocacy program, PIVOT

Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).

Researchers at Johns Hopkins Kimmel Cancer Center are rapidly advancing the understanding of biological factors, including hormones, as predictors of longer disease-free survival for certain subtypes of breast cancer. The implications for treatment -- especially among younger women -- can be profound, but uncertainties remain and decision-making by patients and their physicians can be complicated.

Of the 165,000 men in the U.S. expected to be diagnosed with prostate cancer this year, about half will have low-risk disease. Many of those patients will opt for active surveillance -- a process in which men with low-risk, slow-growing prostate cancer are regularly monitored to see if the cancer starts to grow and requires treatment.

NIBIB-funded researchers have created a novel, low-cost biosensor to detect HER-2, a breast cancer biomarker in the blood, allowing for a far less invasive diagnostic test than the current practice, a needle biopsy. Scientists at the Universities of Hartford and Connecticut and funded in part by NIBIB, combined microfluidic technology with diagnostics, including electrochemical sensors and biomarkers, into a powerful package that can give results in about 15 minutes.

David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research into cancer's ability to overcome stress, gain drug resistance and metastasize.

A new study finds 29 percent of veterans who underwent recommended screening colonoscopies were uncomfortable with the idea of stopping these screenings when the benefit was expected to be low for them personally.

Camilo Correa, MD, is a surgical oncologist specializing in liver, pancreas, bile duct, and intestinal cancers. A native of Colombia, Correa completed a postdoctoral research fellowship at Harvard Medical School and a clinical fellowship at Memorial Sloan Kettering Cancer Center.

Researchers at Johns Hopkins Medicine have developed a new molecular tool they call EXoO, which decodes where on proteins specific sugars are attached--a possible modification due to disease. The study, published in issue 14 of Molecular Systems Biology, describes the development of the tool and its successful use on human blood, tumors and immune cells.

Scientists at Washington University School of Medicine in St. Louis have developed a new tool described as a "flight data recorder" for developing cells, illuminating the paths cells take as they progress from one type to another. This cellular tracking device could one day help scientists guide cells along the right paths to regenerate certain tissues or organs, or help study the origins of cancer.

University of California San Diego School of Medicine researchers engineered sensors to detect and measure the metastatic potential of single cancer cells. Metastasis is attributed as the leading cause of death in people with cancer.

It is an often case that one's health and life depend on as quick a disease is found. That is why today the ways of quick and effective revealing of a disease is one of the most important directions in medicine.

Scientists of the Faculty of Physics of the SUSU Institute of Natural Sciences and Mathematics predict new optical effects in light beams which in perspective will help create technologies of the future, and even reveal cancer in early stages.

UC San Diego Medical Center in Hillcrest was named a Top Teaching Hospital by The Leapfrog Group. The award is widely acknowledged as one of the most competitive honors that a U.S. hospital can receive.

The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center, the world's first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has announced Maria Jasin, PhD, as the recipient of the sixth annual Basser Global Prize. Jasin is a member of the Developmental Biology Program at Memorial Sloan Kettering Cancer Center and a professor at the Weill Graduate School of Medical Sciences at Cornell University.

At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger researchers revealed preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.

A research team has developed a non-invasive method for detecting bladder cancer that might make screening easier and more accurate than current invasive clinical tests involving visual inspection of bladder. In the first successful use of atomic force microscopy (AFM) for clinical diagnostic purposes, the researchers have been able to identify signature features of cancerous cells found in patients' urine by developing a nanoscale resolution map of the cells' surface.

Patients diagnosed with pancreatic cancer face a poor prognosis because the tumor forms dense scar-like tissue that is difficult for chemotherapy drugs to penetrate, but a new model may help researchers develop new therapies.

NEW YORK, NY -- December 3, 2018 -- MDCalc, the global leader in online evidence-based medical calculators, has launched its new guideline summaries in a public beta. The first set of 11 summaries debuted at the annual scientific meeting of the American College of Gastroenterology (ACG) in Philadelphia in early October 2018.

Following the Food and Drug Administration's approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.

The American Society for Radiation Oncology (ASTRO) recently named three leaders in radiation oncology as the recipients of its Gold Medal award. Patricia Eifel, MD, FASTRO, David Jaffray, PhD, and Ralph Weichselbaum, MD, were awarded the highest honor bestowed upon ASTRO members and recognized for their achievements at ASTRO's 60th Annual Meeting in San Antonio.

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. The study, co-led by Sattva Neelapu, M.D., professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, reported its findings in the Dec. 2 online issue of The Lancet Oncology and during a presentation at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

Systems biology analyses by Rutgers Cancer Institute of New Jersey researchers examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma suggest calcium signaling may have an influence in addressing this treatment obstacle.

An investigational immunotherapy drug has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. The lead investigator from Rutgers Cancer Institute of New Jersey shares more on the phase 1 trial.

An international phase-2 trial of a CAR-T cell therapy--to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)--found that 52% of patients responded favorably to the therapy; 40% had a complete response and 12% had a partial response. One year later, 65% of those patients were relapse-free, including 79% of complete responders. The median progression-free survival "has not been reached."

A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.

Preclinical experiments by University of Alabama at Birmingham researchers suggest the cancer drugs vorinostat, belinostat and panobinostat might be repurposed to treat infections caused by human papillomaviruses, or HPVs.

The 60th Annual Meeting of the American Society of Hematology will feature research from St. Jude Children's Research Hospital on topics ranging from the genomic basis and vulnerabilities of leukemia to an update on gene therapy for hemophilia B to advances in sickle cell disease and beta-thalassemia.

Moores Cancer Center at UC San Diego Health launched the Pancreatic Cancer Prevention and Screening Clinic in an attempt to reduce the number of people who develop the disease and improve survival for those who do. Every day in the U.S., 145 people are diagnosed and every 12 minutes someone dies.

A new option - a combination of a standard drug and the novel agent venetoclax - has been granted accelerated approval by the Food and Drug Administration for certain AML patients after a large, multicenter phase 1 clinical trial showed the combination had "promising efficacy" and was well tolerated in older AML patients.

Researchers at UC San Diego used materials like clay and plastic to create synthetic cells--or "cell-mimics"--capable of gene expression and communication rivaling that of living cells. According to some scientists, these newly published research results could be among the most important in synthetic biology this year.

The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.

Bioengineers have developed a 3D bioprinting technique that works with natural materials and is easy to use, allowing researchers of varying levels of technical expertise to create lifelike tissues, such as blood vessels and a vascularized gut. The goal is to make human organ models that can be studied outside the body or used to test new drugs ex vivo.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.

New accelerator-based technology being developed by the Department of Energy's SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second. Built into future compact medical devices, technology developed for high-energy physics could also help make radiation therapy more accessible around the world.

Richard Goldberg, who directs the West Virginia University Cancer Institute, is searching for new ways to slow colorectal cancer's progression. In a recent study, he and an international team of scientists investigated a new drug combination for treating metastatic colorectal cancer in patients who had no--or only temporary--success with conventional chemotherapy treatments.

A $2 million grant from the National Cancer Institute will support the expansion of Rutgers Cancer Institute of New Jersey research focused on sun protective behaviors among young melanoma survivors -- an intervention delivered through social media.

ASRA has awarded the 2018 Chronic Pain Medicine Research Grant to Eellan Sivanesan, MD, for a project looking at the effectiveness of spinal cord stimulation (SCS) for the treatment of chemotherapy-induced painful neuropathy (CIPN). Sivanesan is an assistant professor in the department of anesthesiology and critical care medicine at Johns Hopkins University School of Medicine in Baltimore, MD.

The 2018 recipient of the E.E. Just Award is Guillermina (Gigi) Lozano, professor and chair of the Department of Genetics, Division of Basic Science Research at the University of Texas MD Anderson Cancer Center in Houston. Lozano will present the E.E. Just Award Lecture on Sunday, December 9, at 11:00 am at the 2018 ASCB|EMBO Meeting.

In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients -- ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.

A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the U.S.

Penn researchers will present findings at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, including studies that evaluate CAR T combinations, how the timing of CAR T therapy may impact its effectiveness, and which patients who currently aren't eligible for CAR T therapy should have greater access.

Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may not.

Researchers in Israel have discovered that breast tumors can boost their growth by recruiting stromal cells originally formed in the bone marrow. The study, which will be published November 23 in the Journal of Experimental Medicine, reveals that the recruitment of bone marrow-derived fibroblasts lowers the odds of surviving breast cancer, but suggests that targeting these cells could be an effective way of treating the disease.

Cigarette smoking dramatically decreased between 2013 and 2017 just as e-cigarette use became more popular, according to a comprehensive analysis examining the relationship between vaping and smoking among youth and young adults led by a Georgetown University investigator.

The OARtrac(r) system, built by RadiaDyne and including technologies developed by scientists at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility, has been awarded a 2018 R&D 100 Award by R&D Magazine.

A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.

A new study by University of Minnesota biomedical engineers shows how they stopped cancer cells from moving and spreading, even when the cells changed their movements. The discovery could have a major impact on millions of people undergoing therapies to prevent the spread of cancer within the body.

In a study published in the journal NPJ Breast Cancer, researchers reported they used a form of artificial intelligence called machine learning, or deep learning, to train a computer to identify certain features of breast cancer tumors from images.

A new frontier in the science of circadian rhythms - whose disruption is linked to major diseases like cancer and diabetes - suggests a previously unknown mechanism at work in our daily biological cycle.

The Association of American Cancer Institutes is excited to announce the launch of its redesigned website (aaci-cancer.org). The revamped internet presence will enhance communication between AACI and its 98 cancer center members and within the cancer research and advocacy community.

New research published in JNCCN-Journal of the National Comprehensive Cancer Network found Latino men were 21% less likely to receive definitive treatment compared to non-Latino white men, with significant differences for younger patients, the uninsured, and those treated at NCI-designated centers.

University of Nebraska Medical Center leading national team to determine if ruxolitinib is effective for treating a certain type of graft versus host disease (GVHD) called sclerotic. The grant is funded by Incyte, a global biopharmaceutical company.

A new special edition of the International Journal of Radiation Oncology*Biology*Physics (Red Journal) focuses on the roles of imaging in radiation oncology. The collection explores topics such as improving accuracy with patient positioning, defining radiation therapy volumes using imaging, imaging of functional biomarkers, the role of imaging in post-treatment care, machine learning and artificial intelligence.

Research from investigators at Rutgers Cancer Institute of New Jersey shows that the cell recycling process of autophagy maintains an important tumor nutrient, arginine, in the blood supply, identifying a metabolic vulnerability of cancer.

A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp has demonstrated high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive - and often fatal bone marrow and blood disorder - for which there are no existing approved therapies.

A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

IU scientists have found that drug-delivering nanoparticles attach to their targets differently based upon their position in time. The discovery could improve methods for screening drugs for therapeutic effectiveness.

A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give cancer doctors important new information when choosing drugs and other treatments for cancer patients.